FDA Inspection 1056839 — Hyundai Bioscience Co., Ltd.

Hyundai Bioscience Co., Ltd. — FEI 3010115702

The FDA completed an inspection of Hyundai Bioscience Co., Ltd. on June 22, 2018 in Gimcheon. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 9 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 22, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Gimcheon (Korea (the Republic of))

Citations

IDCFRDescription
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
188321 CFR 211.165(a)Testing and release for distribution
189021 CFR 211.165(e)Test methods
192021 CFR 211.166(a)(3)Valid stability test methods
203121 CFR 211.194(a)Complete test data included in records
355921 CFR 211.56(a)Sanitation--buildings not clean, free of infestation
360321 CFR 211.160(b)Scientifically sound laboratory controls
434921 CFR 211.160(b)(2)In-process samples representative, identified properly
439121 CFR 211.180(e)(2)Items to cover on annual reviews